Skip to main content
Erschienen in: Clinical Research in Cardiology 12/2013

01.12.2013 | Review

Does cirrhotic cardiomyopathy exist? 50 years of uncertainty

verfasst von: Pierpaolo Pellicori, Concetta Torromeo, Angela Calicchia, Alessandra Ruffa, Martina Di Iorio, John G. F. Cleland, Manuela Merli

Erschienen in: Clinical Research in Cardiology | Ausgabe 12/2013

Einloggen, um Zugang zu erhalten

Abstract

Subtle abnormalities of cardiac structure or function are often identified in patients with liver cirrhosis and have been termed cirrhotic cardiomyopathy. However, in the absence of a precise definition, its diagnosis remains a challenge. Cardiac dysfunction in patients with cirrhosis can often be attributed to concomitant diseases such as hypertension, ischaemic heart disease or excess alcohol consumption in many patients. Further research is required to identify the existence, origin and importance of abnormal cardiac function due specifically to liver disease. Cardiac dysfunction may be masked by treatments given to cirrhotic patients, such as mineral-corticoid receptor antagonists, or by co-existing conditions, such as anaemia. New imaging tests or plasma biomarkers might be able to detect abnormal cardiac function at an early stage of its development.
Literatur
1.
2.
Zurück zum Zitat Rayes N, Bechstein WO, Keck H et al (1995) Causes of death after liver transplantation: an analysis of 41 cases in 382 patients. Zentralblatt Chir 120:435–438 Rayes N, Bechstein WO, Keck H et al (1995) Causes of death after liver transplantation: an analysis of 41 cases in 382 patients. Zentralblatt Chir 120:435–438
3.
Zurück zum Zitat Wong F, Girgrah N, Graba J, Allidina Y, Liu P, Blendis L (2001) The cardiac response to exercise in cirrhosis. Gut 49:268–275PubMedCrossRef Wong F, Girgrah N, Graba J, Allidina Y, Liu P, Blendis L (2001) The cardiac response to exercise in cirrhosis. Gut 49:268–275PubMedCrossRef
4.
Zurück zum Zitat Kim MY, Baik SK, Won CS et al (2010) Dobutamine stress echocardiography for evaluating cirrhotic cardiomyopathy in liver cirrhosis. Korean J Hepatol 16:376–382PubMedCrossRef Kim MY, Baik SK, Won CS et al (2010) Dobutamine stress echocardiography for evaluating cirrhotic cardiomyopathy in liver cirrhosis. Korean J Hepatol 16:376–382PubMedCrossRef
5.
Zurück zum Zitat Zieve L (1958) Jaundice, hyperlipemia and hemolytic anemia: a heretofore unrecognized syndrome associated with alcoholic fatty liver and cirrhosis. Ann Intern Med 48:471–496PubMedCrossRef Zieve L (1958) Jaundice, hyperlipemia and hemolytic anemia: a heretofore unrecognized syndrome associated with alcoholic fatty liver and cirrhosis. Ann Intern Med 48:471–496PubMedCrossRef
6.
7.
Zurück zum Zitat Kowalski HJ, Abelmann WH (1953) The cardiac output at rest in Laennec’s cirrhosis. J Clin Invest 32:1025–1033PubMedCrossRef Kowalski HJ, Abelmann WH (1953) The cardiac output at rest in Laennec’s cirrhosis. J Clin Invest 32:1025–1033PubMedCrossRef
8.
Zurück zum Zitat Limas CJ, Guiha NH, Lekagul O et al (1974) Impaired left ventricular function in alcoholic cirrhosis with ascites. Ineffectiveness of ouabain. Circulation 49:754–760PubMedCrossRef Limas CJ, Guiha NH, Lekagul O et al (1974) Impaired left ventricular function in alcoholic cirrhosis with ascites. Ineffectiveness of ouabain. Circulation 49:754–760PubMedCrossRef
9.
Zurück zum Zitat Merli M, Calicchia A, Ruffa A et al (2013) Cardiac dysfunction in cirrhosis is not associated with the severity of liver disease. Eur J Intern Med 24:172–176PubMedCrossRef Merli M, Calicchia A, Ruffa A et al (2013) Cardiac dysfunction in cirrhosis is not associated with the severity of liver disease. Eur J Intern Med 24:172–176PubMedCrossRef
10.
Zurück zum Zitat Ma Z, Lee SS (1996) Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatology 24:451–459PubMedCrossRef Ma Z, Lee SS (1996) Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatology 24:451–459PubMedCrossRef
12.
Zurück zum Zitat Zardi EM, Abbate A, Zardi DM et al (2010) Cirrhotic cardiomyopathy. J Am Coll Cardiol 56:539–549PubMedCrossRef Zardi EM, Abbate A, Zardi DM et al (2010) Cirrhotic cardiomyopathy. J Am Coll Cardiol 56:539–549PubMedCrossRef
13.
Zurück zum Zitat Lunseth JH, Olmstead EG, Abboud F (1958) A study of heart disease in one hundred eight hospitalized patients dying with portal cirrhosis. Arch Intern Med 102:405–413CrossRef Lunseth JH, Olmstead EG, Abboud F (1958) A study of heart disease in one hundred eight hospitalized patients dying with portal cirrhosis. Arch Intern Med 102:405–413CrossRef
14.
Zurück zum Zitat Ortiz-Olvera NX, Castellanos-Pallares G, Gómez-Jiménez LM et al (2011) Anatomical cardiac alterations in liver cirrhosis: an autopsy study. Ann Hepatol 10:321–326PubMed Ortiz-Olvera NX, Castellanos-Pallares G, Gómez-Jiménez LM et al (2011) Anatomical cardiac alterations in liver cirrhosis: an autopsy study. Ann Hepatol 10:321–326PubMed
15.
Zurück zum Zitat Bernardi M, Calandra S, Colantoni A et al (1998) Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 27:28–34PubMedCrossRef Bernardi M, Calandra S, Colantoni A et al (1998) Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 27:28–34PubMedCrossRef
16.
Zurück zum Zitat Trevisani F, Merli M, Savelli F et al (2003) QT interval in patients with non-cirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic porto-systemic shunt. J Hepatol 38:461–467PubMedCrossRef Trevisani F, Merli M, Savelli F et al (2003) QT interval in patients with non-cirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic porto-systemic shunt. J Hepatol 38:461–467PubMedCrossRef
17.
Zurück zum Zitat Bal JS, Thuluvath PJ (2003) Prolongation of QTc interval: relationship with etiology and severity of liver disease, mortality and liver transplantation. Liver Int 23:243–248PubMedCrossRef Bal JS, Thuluvath PJ (2003) Prolongation of QTc interval: relationship with etiology and severity of liver disease, mortality and liver transplantation. Liver Int 23:243–248PubMedCrossRef
18.
Zurück zum Zitat Zambruni A, Trevisani F, Caraceni P et al (2006) Cardiac electrophysiological abnormalities in patients with cirrhosis. J Hepatol 44:994–1002PubMedCrossRef Zambruni A, Trevisani F, Caraceni P et al (2006) Cardiac electrophysiological abnormalities in patients with cirrhosis. J Hepatol 44:994–1002PubMedCrossRef
19.
Zurück zum Zitat Hansen S, Møller S, Bendtsen F et al (2007) Diurnal variation and dispersion in QT interval in cirrhosis: relation to haemodynamic changes. J Hepatol 47:373–380PubMedCrossRef Hansen S, Møller S, Bendtsen F et al (2007) Diurnal variation and dispersion in QT interval in cirrhosis: relation to haemodynamic changes. J Hepatol 47:373–380PubMedCrossRef
20.
Zurück zum Zitat Trevisani F, Di Micoli A, Zambruni A et al (2012) QT interval prolongation by acute gastrointestinal bleeding in patients with cirrhosis. Liver Int 32:1510–1515PubMedCrossRef Trevisani F, Di Micoli A, Zambruni A et al (2012) QT interval prolongation by acute gastrointestinal bleeding in patients with cirrhosis. Liver Int 32:1510–1515PubMedCrossRef
21.
Zurück zum Zitat Wong F, Liu P, Lilly L et al (1999) Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. Clin Sci (Lond) 97:259–267CrossRef Wong F, Liu P, Lilly L et al (1999) Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. Clin Sci (Lond) 97:259–267CrossRef
22.
Zurück zum Zitat Torregrosa M, Aguadé S, Dos L et al (2005) Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol 42(1):68–74PubMedCrossRef Torregrosa M, Aguadé S, Dos L et al (2005) Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol 42(1):68–74PubMedCrossRef
23.
Zurück zum Zitat Kazankov K, Holland-Fischer P, Andersen NH et al (2011) Resting myocardial dysfunction in cirrhosis quantified by tissue Doppler imaging. Liver Int 31:534–540PubMedCrossRef Kazankov K, Holland-Fischer P, Andersen NH et al (2011) Resting myocardial dysfunction in cirrhosis quantified by tissue Doppler imaging. Liver Int 31:534–540PubMedCrossRef
24.
Zurück zum Zitat Pozzi M, Carugo S, Boari G et al (1997) Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology 26:1131–1137PubMed Pozzi M, Carugo S, Boari G et al (1997) Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology 26:1131–1137PubMed
25.
Zurück zum Zitat Bansal S, Lindenfeld J, Schrier RW (2009) Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist? Circ Heart Fail 2:370–376PubMedCrossRef Bansal S, Lindenfeld J, Schrier RW (2009) Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist? Circ Heart Fail 2:370–376PubMedCrossRef
26.
Zurück zum Zitat Pozzi M, Grassi G, Ratti L et al (2005) Cardiac, neuroadrenergic, and portal hemodynamic effects of prolonged aldosterone blockade in postviral child A cirrhosis. Am J Gastroenterol 100:1110–1116PubMedCrossRef Pozzi M, Grassi G, Ratti L et al (2005) Cardiac, neuroadrenergic, and portal hemodynamic effects of prolonged aldosterone blockade in postviral child A cirrhosis. Am J Gastroenterol 100:1110–1116PubMedCrossRef
27.
Zurück zum Zitat Merli M, Valeriano V, Funaro S et al (2002) Modifications of cardiac function in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (TIPS). Am J Gastroenterol 97:142–148PubMedCrossRef Merli M, Valeriano V, Funaro S et al (2002) Modifications of cardiac function in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (TIPS). Am J Gastroenterol 97:142–148PubMedCrossRef
28.
Zurück zum Zitat McMurray JJ, Adamopoulos S, Anker SD et al (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 14:803–869PubMedCrossRef McMurray JJ, Adamopoulos S, Anker SD et al (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 14:803–869PubMedCrossRef
29.
Zurück zum Zitat Pitt B, Zannad F, Remme WJ et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709–717PubMedCrossRef Pitt B, Zannad F, Remme WJ et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709–717PubMedCrossRef
30.
Zurück zum Zitat Zannad F, McMurray JJ, Krum H et al (2011) EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364:11–21PubMedCrossRef Zannad F, McMurray JJ, Krum H et al (2011) EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364:11–21PubMedCrossRef
31.
Zurück zum Zitat Desai AS, Lewis EF, Li R et al (2011) Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J 162:966–972PubMedCrossRef Desai AS, Lewis EF, Li R et al (2011) Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J 162:966–972PubMedCrossRef
32.
Zurück zum Zitat Rossi GP, Sacchetto A, Pavan E et al (1997) Remodeling of the left ventricle in primary aldosteronism due to Conn’s adenoma. Circulation 95(6):1471–1478PubMedCrossRef Rossi GP, Sacchetto A, Pavan E et al (1997) Remodeling of the left ventricle in primary aldosteronism due to Conn’s adenoma. Circulation 95(6):1471–1478PubMedCrossRef
33.
Zurück zum Zitat Reil JC, Hohl M, Selejan S et al (2012) Aldosterone promotes atrial fibrillation. Eur Heart J 33(16):2098–2108PubMedCrossRef Reil JC, Hohl M, Selejan S et al (2012) Aldosterone promotes atrial fibrillation. Eur Heart J 33(16):2098–2108PubMedCrossRef
34.
Zurück zum Zitat Pellicori P, Carubelli V, Zhang J et al (2013) IVC diameter in patients with chronic heart failure: relationships and prognostic significance. JACC Cardiovasc Imaging 6:16–28PubMedCrossRef Pellicori P, Carubelli V, Zhang J et al (2013) IVC diameter in patients with chronic heart failure: relationships and prognostic significance. JACC Cardiovasc Imaging 6:16–28PubMedCrossRef
35.
Zurück zum Zitat Ayers CR, Davis JO, Lieberman F et al (1962) The effects of chronic hepatic venous congestion on the metabolism of d, l-aldosterone and d-aldosterone. J Clin Invest 41:884–895PubMedCrossRef Ayers CR, Davis JO, Lieberman F et al (1962) The effects of chronic hepatic venous congestion on the metabolism of d, l-aldosterone and d-aldosterone. J Clin Invest 41:884–895PubMedCrossRef
36.
Zurück zum Zitat Swedberg K, Komajda M, Böhm M et al (2010) SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376:875–885PubMedCrossRef Swedberg K, Komajda M, Böhm M et al (2010) SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376:875–885PubMedCrossRef
37.
Zurück zum Zitat Fox K, Ford I, Steg PG, BEAUTIFUL Investigators et al (2008) Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 372(9641):807–816PubMedCrossRef Fox K, Ford I, Steg PG, BEAUTIFUL Investigators et al (2008) Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 372(9641):807–816PubMedCrossRef
38.
Zurück zum Zitat Tan YT, Wenzelburger F, Lee E et al (2009) The pathophysiology of heart failure with normal ejection fraction: exercise echocardiography reveals complex abnormalities of both systolic and diastolic ventricular function involving torsion, untwist, and longitudinal motion. J Am Coll Cardiol 54:36–46PubMedCrossRef Tan YT, Wenzelburger F, Lee E et al (2009) The pathophysiology of heart failure with normal ejection fraction: exercise echocardiography reveals complex abnormalities of both systolic and diastolic ventricular function involving torsion, untwist, and longitudinal motion. J Am Coll Cardiol 54:36–46PubMedCrossRef
39.
Zurück zum Zitat Nikitin NP, Witte KKA, Thackray SDR et al (2003) Longitudinal ventricular function: normal values of atrioventricular annular and myocardial velocities measured with color tissue Doppler imaging. J Am Soc Echo 16:906–921CrossRef Nikitin NP, Witte KKA, Thackray SDR et al (2003) Longitudinal ventricular function: normal values of atrioventricular annular and myocardial velocities measured with color tissue Doppler imaging. J Am Soc Echo 16:906–921CrossRef
40.
Zurück zum Zitat Richand V, Lafitte S, Reant P et al (2007) An ultrasound speckle tracking (two-dimensional strain) analysis of myocardial deformation in professional soccer players compared with healthy subjects and hypertrophic cardiomyopathy. Am J Cardiol 100:128–132PubMedCrossRef Richand V, Lafitte S, Reant P et al (2007) An ultrasound speckle tracking (two-dimensional strain) analysis of myocardial deformation in professional soccer players compared with healthy subjects and hypertrophic cardiomyopathy. Am J Cardiol 100:128–132PubMedCrossRef
41.
Zurück zum Zitat Galderisi M, Lomoriello VS, Santoro A et al (2010) Differences of myocardial systolic deformation and correlates of diastolic function in competitive rowers and young hypertensives: a speckle-tracking echocardiography study. J Am Soc Echocardiogr 23:1190–1198PubMedCrossRef Galderisi M, Lomoriello VS, Santoro A et al (2010) Differences of myocardial systolic deformation and correlates of diastolic function in competitive rowers and young hypertensives: a speckle-tracking echocardiography study. J Am Soc Echocardiogr 23:1190–1198PubMedCrossRef
42.
Zurück zum Zitat La Villa G, Romanelli RG, Casini Raggi V et al (1992) Plasma levels of brain natriuretic peptide in patients with cirrhosis. Hepatology 16:156–161PubMedCrossRef La Villa G, Romanelli RG, Casini Raggi V et al (1992) Plasma levels of brain natriuretic peptide in patients with cirrhosis. Hepatology 16:156–161PubMedCrossRef
43.
Zurück zum Zitat Wong F, Siu S, Liu P et al (2001) Brain natriuretic peptide: is it a predictor of cardiomyopathy in cirrhosis? Clin Sci (Lond) 101:621–628CrossRef Wong F, Siu S, Liu P et al (2001) Brain natriuretic peptide: is it a predictor of cardiomyopathy in cirrhosis? Clin Sci (Lond) 101:621–628CrossRef
44.
Zurück zum Zitat Henriksen JH, Gøtze JP, Fuglsang S et al (2003) Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 52:1511–1517PubMedCrossRef Henriksen JH, Gøtze JP, Fuglsang S et al (2003) Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 52:1511–1517PubMedCrossRef
45.
Zurück zum Zitat Pimenta J, Paulo C, Gomes A et al (2010) B-type natriuretic peptide is related to cardiac function and prognosis in hospitalized patients with decompensated cirrhosis. Liver Int 30:1059–1066PubMedCrossRef Pimenta J, Paulo C, Gomes A et al (2010) B-type natriuretic peptide is related to cardiac function and prognosis in hospitalized patients with decompensated cirrhosis. Liver Int 30:1059–1066PubMedCrossRef
46.
Zurück zum Zitat Vasatova M, Pudil R, Safka V et al (2013) Elevated cardiac markers are associated with higher mortality in patients after transjugular intrahepatic portosystemic shunt insertion. Ann Clin Biochem 50(Pt 2):122–126PubMedCrossRef Vasatova M, Pudil R, Safka V et al (2013) Elevated cardiac markers are associated with higher mortality in patients after transjugular intrahepatic portosystemic shunt insertion. Ann Clin Biochem 50(Pt 2):122–126PubMedCrossRef
47.
Zurück zum Zitat Yang RY, Rabinovich GA, Liu FT (2008) Galectins: structure, function and therapeutic potential. Expert Rev Mol Med 13:e17–e39CrossRef Yang RY, Rabinovich GA, Liu FT (2008) Galectins: structure, function and therapeutic potential. Expert Rev Mol Med 13:e17–e39CrossRef
48.
Zurück zum Zitat Sharma UC, Pokharel S, van Brakel TJ et al (2004) Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 110:3121–3128PubMedCrossRef Sharma UC, Pokharel S, van Brakel TJ et al (2004) Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 110:3121–3128PubMedCrossRef
49.
Zurück zum Zitat Lin YH, Lin LY, Wu YW et al (2009) The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta 409:96–99PubMedCrossRef Lin YH, Lin LY, Wu YW et al (2009) The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta 409:96–99PubMedCrossRef
50.
Zurück zum Zitat de Boer RA, Lok DJ, Jaarsma T et al (2011) Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 43:60–68PubMedCrossRef de Boer RA, Lok DJ, Jaarsma T et al (2011) Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 43:60–68PubMedCrossRef
51.
Zurück zum Zitat de Boer RA, van Veldhuisen DJ, Gansevoort RT et al (2012) The fibrosis marker galectin-3 and outcome in the general population. J Intern Med 272:55–64PubMedCrossRef de Boer RA, van Veldhuisen DJ, Gansevoort RT et al (2012) The fibrosis marker galectin-3 and outcome in the general population. J Intern Med 272:55–64PubMedCrossRef
52.
Zurück zum Zitat Henderson NC, Mackinnon AC, Farnworth SL et al (2006) Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA 103:5060–5065PubMedCrossRef Henderson NC, Mackinnon AC, Farnworth SL et al (2006) Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA 103:5060–5065PubMedCrossRef
53.
Zurück zum Zitat Butscheid M, Hauptvogel P, Fritz P et al (2007) Hepatic expression of galectin-3 and receptor for advanced glycation end products in patients with liver disease. J Clin Pathol 60:415–418PubMedCrossRef Butscheid M, Hauptvogel P, Fritz P et al (2007) Hepatic expression of galectin-3 and receptor for advanced glycation end products in patients with liver disease. J Clin Pathol 60:415–418PubMedCrossRef
54.
Zurück zum Zitat Yilmaz Y, Eren F, Kurt R et al (2011) Serum galectin-3 levels in patients with nonalcoholic fatty liver disease. Clin Biochem 44:955–958PubMedCrossRef Yilmaz Y, Eren F, Kurt R et al (2011) Serum galectin-3 levels in patients with nonalcoholic fatty liver disease. Clin Biochem 44:955–958PubMedCrossRef
55.
Zurück zum Zitat Cheung KJ, Libbrecht L, Tilleman K et al (2010) Galectin-3-binding protein: a serological and histological assessment in accordance with hepatitis C-related liver fibrosis. Eur J Gastroenterol Hepatol 22:1066–1073PubMedCrossRef Cheung KJ, Libbrecht L, Tilleman K et al (2010) Galectin-3-binding protein: a serological and histological assessment in accordance with hepatitis C-related liver fibrosis. Eur J Gastroenterol Hepatol 22:1066–1073PubMedCrossRef
56.
Zurück zum Zitat de Oliveira SA, de Freitas Souza BS, Sá Barreto EP et al (2012) Reduction of galectin-3 expression and liver fibrosis after cell therapy in a mouse model of cirrhosis. Cytotherapy 14:339–349PubMedCrossRef de Oliveira SA, de Freitas Souza BS, Sá Barreto EP et al (2012) Reduction of galectin-3 expression and liver fibrosis after cell therapy in a mouse model of cirrhosis. Cytotherapy 14:339–349PubMedCrossRef
57.
Zurück zum Zitat Wanninger J, Weigert J, Wiest R et al (2011) Systemic and hepatic vein galectin-3 are increased in patients with alcoholic liver cirrhosis and negatively correlate with liver function. Cytokine 55:435–440PubMedCrossRef Wanninger J, Weigert J, Wiest R et al (2011) Systemic and hepatic vein galectin-3 are increased in patients with alcoholic liver cirrhosis and negatively correlate with liver function. Cytokine 55:435–440PubMedCrossRef
58.
Zurück zum Zitat Cazzaniga M, Salerno F, Pagnozzi G et al (2007) Diastolic dysfunction is associated with poor survival in patients with cirrhosis with transjugular intrahepatic portosystemic shunt. Gut 56:869–875PubMedCrossRef Cazzaniga M, Salerno F, Pagnozzi G et al (2007) Diastolic dysfunction is associated with poor survival in patients with cirrhosis with transjugular intrahepatic portosystemic shunt. Gut 56:869–875PubMedCrossRef
59.
Zurück zum Zitat Rabie RN, Cazzaniga M, Salerno F et al (2009) The use of E/A ratio as a predictor of outcome in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt. Am J Gastroenterol 104:2458–2466PubMedCrossRef Rabie RN, Cazzaniga M, Salerno F et al (2009) The use of E/A ratio as a predictor of outcome in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt. Am J Gastroenterol 104:2458–2466PubMedCrossRef
60.
Zurück zum Zitat Krag A, Bendtsen F, Henriksen JH et al (2010) Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut 59:105–110PubMedCrossRef Krag A, Bendtsen F, Henriksen JH et al (2010) Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut 59:105–110PubMedCrossRef
61.
Zurück zum Zitat Alexopoulou A, Papatheodoridis G, Pouriki S et al (2012) Diastolic myocardial dysfunction does not affect survival in patients with cirrhosis. Transpl Int 25:1174–1181PubMedCrossRef Alexopoulou A, Papatheodoridis G, Pouriki S et al (2012) Diastolic myocardial dysfunction does not affect survival in patients with cirrhosis. Transpl Int 25:1174–1181PubMedCrossRef
62.
Zurück zum Zitat Nazar A, Guevara M, Sitges M et al (2013) Left ventricular function assessed by echocardiography in cirrhosis. Relationship to systemic hemodynamics and renal dysfunction. J Hepatol 58:51–57PubMedCrossRef Nazar A, Guevara M, Sitges M et al (2013) Left ventricular function assessed by echocardiography in cirrhosis. Relationship to systemic hemodynamics and renal dysfunction. J Hepatol 58:51–57PubMedCrossRef
63.
Zurück zum Zitat Woo JJ, Koh YY, Kim HJ et al (2008) N-terminal pro B-type natriuretic peptide and the evaluation of cardiac dysfunction and severity of disease in cirrhotic patients. Yonsei Med J 49:625–631PubMedCrossRef Woo JJ, Koh YY, Kim HJ et al (2008) N-terminal pro B-type natriuretic peptide and the evaluation of cardiac dysfunction and severity of disease in cirrhotic patients. Yonsei Med J 49:625–631PubMedCrossRef
64.
Zurück zum Zitat Ziada D, Gaber R, Kotb N et al (2011) Predictive value of N-terminal pro B-type natriuretic peptide in tissue Doppler-diagnosed cirrhotic cardiomyopathy. Heart Mirror J 5:264–270 Ziada D, Gaber R, Kotb N et al (2011) Predictive value of N-terminal pro B-type natriuretic peptide in tissue Doppler-diagnosed cirrhotic cardiomyopathy. Heart Mirror J 5:264–270
65.
Zurück zum Zitat Enache I, Oswald-Mammosser M, Woehl-Jaegle ML et al (2013) Cirrhotic cardiomyopathy and hepatopulmonary syndrome: prevalence and prognosis in a series of patients. Respir Med 107:1030–1036PubMedCrossRef Enache I, Oswald-Mammosser M, Woehl-Jaegle ML et al (2013) Cirrhotic cardiomyopathy and hepatopulmonary syndrome: prevalence and prognosis in a series of patients. Respir Med 107:1030–1036PubMedCrossRef
Metadaten
Titel
Does cirrhotic cardiomyopathy exist? 50 years of uncertainty
verfasst von
Pierpaolo Pellicori
Concetta Torromeo
Angela Calicchia
Alessandra Ruffa
Martina Di Iorio
John G. F. Cleland
Manuela Merli
Publikationsdatum
01.12.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Clinical Research in Cardiology / Ausgabe 12/2013
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-013-0610-1

Weitere Artikel der Ausgabe 12/2013

Clinical Research in Cardiology 12/2013 Zur Ausgabe

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Intervallfasten zur Regeneration des Herzmuskels?

14.05.2024 Herzinfarkt Nachrichten

Die Nahrungsaufnahme auf wenige Stunden am Tag zu beschränken, hat möglicherweise einen günstigen Einfluss auf die Prognose nach akutem ST-Hebungsinfarkt. Darauf deutet eine Studie an der Uniklinik in Halle an der Saale hin.

Shunt-Therapie bei Herzinsuffizienz: Kein Anzug, der allen passt

13.05.2024 Chronische Herzinsuffizienz Nachrichten

Die Anlage eines interatrialen Shunts zur Reduktion des linksatrialen Drucks ist ein neuer Therapieansatz bei Herzinsuffizienz. Viele Patienten sprechen darauf an, andere jedoch nicht. 

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.